What is the Amgen v. Sanofi Supreme Court case about?

It's testing if patents must enable their full claim scope without undue experimentation under §112, focused on Amgen's Repatha antibody patents.

How could Amgen v. Sanofi affect biotech patents?

Affirmance likely tightens functional claims, forcing more disclosures — good for competition, tough on incumbents like Amgen.

Expected spring 2024; decision by June.

©️ IP & Copyright

Eli Lilly isn't mincing words: Amgen's patents are toast under §112. With SCOTUS oral arguments looming, the biotech world holds its breath.

theAIcatchup Apr 09, 2026 3 min read

Federal Circuit's enablement ruling likely affirmed, curbing broad functional biotech claims. 𝕏
Amici heavily favor Sanofi now, signaling market shift against overreach. 𝕏
Precedent like Myriad suggests SCOTUS will prioritize structure over function. 𝕏

Published by

Where law meets technology.

#Amgen v Sanofi #SCOTUS biotech case #patent enablement #§112 functional claims

Get the best Legal Tech stories of the week in your inbox — no noise, no spam.

Originally reported by IPWatchdog